» Articles » PMID: 35837379

Natural Compounds or Their Derivatives Against Breast Cancer: A Computational Study

Abstract

Background: Breast cancer is one of the most common types of cancer diagnosed and the second leading cause of death among women. Breast cancer susceptibility proteins of type 1 and 2 are human tumor suppressor genes. Genetic variations/mutations in these two genes lead to overexpression of human breast tumor suppressor genes (e.g., BRCA1, BRCA2), which triggers uncontrolled duplication of cells in humans. In addition, multidrug resistance protein 1 (MDR1), an important cell membrane protein that pumps many foreign substances from cells, is also responsible for developing resistance to cancer chemotherapy. . The aim of this study was to analyze some natural compounds or their derivatives as part of the development of strong inhibitors for breast cancer. . Molecular docking studies were performed using compounds known in the literature to be effective against BRCA1 and BRCA2 and MDR1, with positive control being 5-fluorouracil, an antineoplastic drug as a positive control.

Results: The binding affinity of the compounds was analyzed, and it was observed that they had a better binding affinity for the target proteins than the standard drug 5-fluorouracil. Among the compounds analyzed, -hederin, andrographolide, apigenin, asiatic acid, auricular acid, sinularin, curcumin, citrinin, hispolon, nerol, phytol, retinol palmitate, and sclareol showed the best binding affinity energy to the BRCA1, BRCA2, and MDR1 proteins, respectively.

Conclusions: -Hederin, andrographolide, apigenin, asiatic acid, auricular acid, hispolon, sclareol, curcumin, citrinin, and sinularin or their derivatives can be a good source of anticancer agents in breast cancer.

Citing Articles

Natural products as drug leads: exploring their potential in drug discovery and development.

Singh K, Gupta J, Chanchal D, Shinde M, Kumar S, Jain D Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39621089 DOI: 10.1007/s00210-024-03622-6.


Detecting the Tumor Prognostic Factors From the YTH Domain Family Through Integrative Pan-Cancer Analysis.

Zhu C, Yang Q, Mu X, Zhai Y, Zhao W, Yin Z Cancer Inform. 2024; 23:11769351241300030.

PMID: 39553336 PMC: 11569503. DOI: 10.1177/11769351241300030.


Revitalizing allicin for cancer therapy: advances in formulation strategies to enhance bioavailability, stability, and clinical efficacy.

Bala R, Madaan R, Chauhan S, Gupta M, Dubey A, Zahoor I Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(2):703-724.

PMID: 37615709 DOI: 10.1007/s00210-023-02675-3.


An updated overview of anticancer effects of alternariol and its derivatives: underlying molecular mechanisms.

Islam M, Martorell M, Gonzalez-Contreras C, Villagran M, Mardones L, Tynybekov B Front Pharmacol. 2023; 14:1099380.

PMID: 37033617 PMC: 10076758. DOI: 10.3389/fphar.2023.1099380.


Anticancer properties of bromelain: State-of-the-art and recent trends.

Pezzani R, Jimenez-Garcia M, Capo X, Sonmez Gurer E, Sharopov F, Lauve Rachel T Front Oncol. 2023; 12:1068778.

PMID: 36698404 PMC: 9869248. DOI: 10.3389/fonc.2022.1068778.


References
1.
Kim Y, Chen J . Molecular structure of human P-glycoprotein in the ATP-bound, outward-facing conformation. Science. 2018; 359(6378):915-919. DOI: 10.1126/science.aar7389. View

2.
Easton D, Ford D, Bishop D . Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995; 56(1):265-71. PMC: 1801337. View

3.
Kar S, Roy K . How far can virtual screening take us in drug discovery?. Expert Opin Drug Discov. 2013; 8(3):245-61. DOI: 10.1517/17460441.2013.761204. View

4.
Khan R, Hossain R, Siyadatpanah A, Al-Khafaji K, Khalipha A, Dey D . Diterpenes/Diterpenoids and Their Derivatives as Potential Bioactive Leads against Dengue Virus: A Computational and Network Pharmacology Study. Molecules. 2021; 26(22). PMC: 8623982. DOI: 10.3390/molecules26226821. View

5.
Sharifi-Rad J, Quispe C, Patra J, Singh Y, Panda M, Das G . Paclitaxel: Application in Modern Oncology and Nanomedicine-Based Cancer Therapy. Oxid Med Cell Longev. 2021; 2021:3687700. PMC: 8545549. DOI: 10.1155/2021/3687700. View